Aspira Pathlab & Diagnostics Ltd Financials
Company Logo

Aspira Pathlab & Diagnostics Ltd Financial Statement

Aspira Pathlab & Diagnostics Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue5.91
Operating Expense4.72
Net Profit0.72
Net Profit Margin12.18
Earning Per Share0.70
EBIDTA1.18
Effective Tax RateTBA

Aspira Pathlab & Diagnostics Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual13.20
Operating Expenses Annual14.39
Operating Profit Annual-0.77
Interest Annual0.37
Depreciation1.51
Net Profit Annual-2.67
Tax AnnualTBA

Aspira Pathlab & Diagnostics Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.57
Cash Flow from Operations1.05
Cash Flow from Investing0.14
Cash Flow from Financing-0.95
Cash Flow at the End0.80

Aspira Pathlab & Diagnostics Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-5.76
PBIT Margin (%)-17.42
PBT Margin (%)29.70
Net PROFIT Margin (%)-20.23
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-18.00
Total Debt / Equity (X)0.16
Asset Turnover Ratio (%)0.89

Aspira Pathlab & Diagnostics Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual6.79
Total Current Assets Annual4.36
Non Current Assets Annual10.35
Total Shareholders Funds Annual10.14
Total Assets Annual14.71

Aspira Pathlab & Diagnostics Ltd Earning Calls

EPS (INR)

Expected

0.66

Reported

0.66

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.00%

FAQS on Aspira Pathlab & Diagnostics Ltd Financials

As of Jun 1, 2025, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 87.73 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Aspira Pathlab & Diagnostics Ltd is with a debt-to-equity ratio of 0.26.

In FY 2024 , Aspira Pathlab & Diagnostics Ltd recorded a total revenue of approximately 22 Cr marking a significant milestone in the company's financial performance.

Aspira Pathlab & Diagnostics Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.6% and 0.2% annually, respectively..

Aspira Pathlab & Diagnostics Ltd's current PE ratio is 42.38.

Aspira Pathlab & Diagnostics Ltd's ROCE averaged -0.0% from the FY ending March 2023 to 2025, with a median of 2.0%. It peaked at 15.7% in March 2025, reflecting strong capital efficiency over the period..

Aspira Pathlab & Diagnostics Ltd's latest EBIT is Rs. 2.42 Cr, surpassing the average EBIT of Rs. 0.15 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions